TB-500
TB-500 (Thymosin Beta-4)
A systemic healing peptide that promotes tissue repair throughout the entire body by regulating cell migration, reducing inflammation, and stimulating new blood vessel formation.
TB-500 is a synthetic version of thymosin beta-4, a naturally occurring protein found in nearly all human and animal cells. The full thymosin beta-4 protein consists of 43 amino acids, and TB-500 is the synthetic analog that retains the key regenerative properties. Your body naturally produces thymosin beta-4 in high concentrations in platelets, white blood cells, plasma, and wound fluid, and it is present in virtually every tissue type except red blood cells.
Thymosin beta-4 was originally discovered in the thymus gland during immune function research in the 1960s. Since then, it has been studied extensively for wound healing, cardiac repair, and tissue regeneration. The World Health Organization has even assigned it the official International Nonproprietary Name 'timbetasin,' reflecting the seriousness with which the scientific community regards this compound.
TB-500 is not FDA approved for human use. In 2023, the FDA classified it as a Category 2 bulk drug substance, effectively prohibiting its use in compounded medications. The World Anti-Doping Agency has banned it under the S0 Unapproved Substances category, and it has been central to major doping controversies in professional sports, including suspensions of players from the Essendon Football Club in Australian football and the Cronulla-Sutherland Sharks rugby team.
How It Works
The primary mechanism of TB-500 involves its role as an actin-binding protein. Actin is one of the most abundant proteins in your cells, making up about 10 percent of total cellular protein, and it forms the structural framework that gives cells their shape and allows them to move. TB-500 binds to individual actin building blocks and prevents them from forming long chains too early. This creates a ready reserve of building blocks that can be rapidly mobilized when cells need to migrate during wound healing. When your body signals that cells need to move, TB-500 releases its bound actin so it can be directed exactly where it is needed.
TB-500 has a unique property among healing factors: it promotes cell migration without binding to the extracellular matrix, the structural scaffolding between cells. Combined with its very low molecular weight, this allows TB-500 to travel long distances through tissues to reach injury sites. This systemic distribution is why TB-500 can be injected anywhere in the body and still affect injuries in distant locations -- you do not need to inject near the wound.
Beyond cell migration, TB-500 promotes new blood vessel formation by upregulating VEGF signaling and directly affecting the behavior of blood vessel cells. It also modulates inflammation by releasing an anti-inflammatory peptide fragment called Ac-SDKP during its metabolism, and it has the capacity to mobilize, recruit, and influence the differentiation of your body's own stem and progenitor cells. In cardiac studies, it was shown to stimulate the formation of new heart muscle cells from precursor cells in the outer lining of adult hearts.
Potential Benefits
Wound Healing
This is the most extensively studied application of TB-500. In animal wound models, topical or systemic administration increased new skin coverage by 42 percent at day 4 and up to 61 percent at day 7 compared to untreated wounds. Wounds also contracted at least 11 percent more than controls by day 7, and researchers observed increased collagen deposition and new blood vessel formation in treated wounds.
Tendon and Ligament Repair
TB-500 promotes the migration of fibroblasts -- the cells responsible for building connective tissue -- into damaged tendons and ligaments, supporting structural repair. It also helps prevent the formation of adhesions and fibrous bands that can restrict movement after injury, which is one of the most common complications of tendon and ligament healing.
Muscle Recovery
Research shows TB-500 acts as a chemical attractant for myoblasts, which are the precursor cells that become new muscle fibers. It draws these cells to injured muscle tissue, supporting faster muscle fiber regeneration after strain or trauma. Studies in mice with a form of muscular dystrophy showed improved skeletal and cardiac muscle function with TB-500 treatment.
Cardiac Protection and Repair
Extensive research has explored TB-500 for heart repair. In mice, administration stimulated the formation of new heart muscle cells, induced migration of repair cells into damaged heart tissue, and recruited new blood vessels within the muscle. Phase 2 clinical trials have explored its use following heart attack, making this one of the more clinically advanced applications.
Eye Healing
TB-500 has been studied for various eye conditions in Phase 2 clinical trials. Results showed it significantly improves dry eye and neurotrophic keratopathy, with effects lasting long after treatment ends. It promotes the synthesis of laminin-332, a protein that maintains the structural connections between cells in the cornea.
Neuroprotection
Animal research indicates TB-500 promotes repair and remodeling of central and peripheral nervous system tissues after injury. Studies show improved blood vessel and neuron growth in damaged brain regions, with clinically significant improvements in behavior, motor control, and cognitive measurements. Recent research also shows TB-500 can reduce oxidative stress following spinal cord injury.
Hair Growth
Some research and user reports suggest TB-500 can promote hair follicle development and growth. While this is not a primary application, it is an additional benefit that some people experience during treatment cycles.
What the Research Shows
A foundational 1999 study by Malinda and colleagues published in the Journal of Investigative Dermatology examined thymosin beta-4's wound healing effects in rat models and found that new skin coverage increased 42 percent at day 4 and 61 percent at day 7 compared to untreated wounds. Wounds also contracted at least 11 percent more, and increased collagen deposition and blood vessel formation were observed. Remarkably, skin cell migration was stimulated 2 to 3 fold at concentrations as low as 10 picograms, demonstrating the peptide's potency at extremely small amounts.
A landmark 2004 study by Bock-Marquette and colleagues published in Nature showed that thymosin beta-4 activates integrin-linked kinase, promotes heart cell migration and survival, and stimulates the formation of new heart muscle cells from precursor cells -- findings that opened up an entirely new area of cardiac repair research. A 2010 study by Spurney and colleagues in PLoS ONE evaluated skeletal and cardiac muscle function after chronic TB-4 administration in mice with a form of muscular dystrophy and showed improved skeletal and cardiac muscle function with long-term tolerability.
Phase 2 clinical trials have produced encouraging human data. Sosne and colleagues published a randomized, placebo-controlled trial in 2015 in Clinical Ophthalmology showing that thymosin beta-4 significantly improved signs and symptoms of severe dry eye, with effects persisting after treatment ended and no serious adverse events. Ruff and colleagues published a 2010 study in the Annals of the New York Academy of Sciences confirming that IV thymosin beta-4 was safe and well tolerated in healthy volunteers with no significant adverse effects. Wang and colleagues confirmed similar safety in Chinese volunteers in a 2021 Phase I study.
What to Know
The most commonly reported side effects include injection site reactions such as redness or irritation, mild fatigue or lethargy, and headache. Flu-like symptoms are occasionally reported but are rare. Nausea and lightheadedness have also been noted by some users.
Because TB-500 promotes the formation of new blood vessels, there is a theoretical concern about its use in individuals with existing cancers or tumors, as new blood vessels could potentially support tumor growth. No evidence has demonstrated this risk in practice, but it remains a concern that warrants caution. The FDA classified TB-500 as a Category 2 bulk drug substance, and WADA has banned it.
Do not use if you have active cancer, tumors, or a history of malignancy. Use caution if you have severe immunodeficiency, active autoimmune conditions, or cardiovascular conditions. Safety has not been established for pregnancy, breastfeeding, or in combination with immunosuppressive medications. A toxicology assessment in rodent models found no significant adverse effects at doses up to 100 mg/kg, indicating a high safety threshold.
Research References
Thymosin beta4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology · 1999
Foundational wound healing study showing thymosin beta-4 increased re-epithelialization by 42% at day 4 and 61% at day 7, improved wound contraction, and stimulated skin cell migration at concentrations as low as 10 picograms.
View StudyThymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair
Bock-Marquette I, Saxena A, White MD, et al. · Nature · 2004
Landmark study demonstrating that thymosin beta-4 activates integrin-linked kinase, promotes cardiac cell migration and survival, and stimulates formation of new heart muscle cells from precursor cells.
View StudyEvaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin Beta-4 in the Dystrophin Deficient Mouse
Spurney CF, Cha HJ, Sali A, et al. · PLoS ONE · 2010
Showed improved skeletal and cardiac muscle function and demonstrated long-term tolerability of thymosin beta-4 in a mouse model of Duchenne muscular dystrophy.
View StudyThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase 2 clinical trial
Sosne G, Ousler GW · Clinical Ophthalmology · 2015
Randomized, placebo-controlled Phase 2 trial showing thymosin beta-4 significantly improved signs and symptoms of severe dry eye, with effects persisting after treatment ended and no serious adverse events.
View StudyA randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers
Ruff D, Crockford D, Girardi G, Zhang Y · Annals of the New York Academy of Sciences · 2010
Established that IV thymosin beta-4 was safe and well tolerated in healthy volunteers with no significant adverse effects, providing preliminary human pharmacokinetic data.
View StudyA first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers
Wang X, Liu L, Qi L, et al. · Journal of Cellular and Molecular Medicine · 2021
Phase I study confirming single and multiple dose administration of thymosin beta-4 was safe and well tolerated in healthy adults, providing additional human pharmacokinetic data.
View StudyThymosin beta4: a multi-functional regenerative peptide
Goldstein AL, Hannappel E, Sosne G, Kleinman HK · Expert Opinion on Biological Therapy · 2012
Comprehensive review of thymosin beta-4 as a multi-functional regenerative peptide covering its roles in wound healing, cardiac repair, neuroprotection, and immune function.
View Study